INTRODUCTION 78
Asthma is a chronic inflammatory airway disease that is characterized by a reversible airway 79 obstruction and airway hyperreactivity 1, 2 . Most patients have an allergic component where 80 the immunoglobulin E (IgE) plays a central role by activating key immune cells through the 81 high affinity IgE receptor, FcεRI 3, 4 . Although treatment with bronchodilators and inhaled 82 glucocorticosteroids (ICS) generally provide good control of the disease, a significant 83 proportion of the asthma patients have persistent symptoms despite conventional therapy 5 . 84
This phenomenon, referred to as uncontrolled asthma 6,7 , represents a major challenge for 85 improved asthma control. 86
87
Despite the clinical significance of uncontrolled asthma, little is known about the 88 inflammatory processes that evoke symptoms in this group of patients. One possibility is 89 existence of steroid-resistant inflammatory components in the central airways 8 . Another 90 alternative is involvement of peripheral airways 9, 10 , which are difficult to reach by 91 conventional inhalation therapy 11 . The few previous studies that have explored transbronchial 92 biopsies from asthmatics provide clear indications that both small airways and alveolar tissues 93 may be subjected to a cellular inflammation in asthma [12] [13] [14] . 94
95
Mast cells have long been recognized as a key cell of the allergic reaction in atopic asthma, by 96 virtue of their expression of FcεRI 15 . They are widely present in high numbers in human 97 peripheral airways, including the alveolar region 10, 12, [16] [17] [18] . We recently identified a distinct 98 mast cell population in the alveolar tissue of normal lungs 19 . These poorly studied alveolar 99 mast cells, which are characterized by a low FcεRI expression, comprise a large mast cell 100 population in the human lung 12, 19, 20 . 101 allergic asthma 10, 12, 17, 21, 22 . From this, and the fact that high IgE-levels may lead to increased 104
FcεRI expression on mast cells 23 , 24 , we hypothesized that patients with ICS-treated, atopic 105 uncontrolled asthma have a significantly altered mast cell population where the normally 106
FcεRI low-expressing alveolar mast cells have acquired an FcεRI-expressing phenotype. To 107 test this hypothesis mast cell densities and mast cell expression of FcεRI and surface-bound 108
IgE were analyzed in bronchial and transbronchial biopsies from atopic, uncontrolled 109 asthmatics and healthy control subjects. Separate comparisons were also made with patients 110 with atopic allergic rhinitis (AR) with no concomitant asthma. 111
METHODS 113 114

Subjects 115
Patients with atopic uncontrolled asthma, non-atopic and atopic control groups: 116
The present study involved 14 non-smoking patients with uncontrolled atopic asthma 117 according to GINA guidelines and asthma control test (ACT) 6, 25 . Eight healthy never-118 smoking non-atopic subjects that had negative skin prick test (SPT), were not hyper-119 responsive to metacholine, and lacked of any history of respiratory symptoms were used as 120 controls. As a separate control group, representing atopy without asthma, included 8 patients 121
with clinically confirmed AR 26 . 122
123
From each of the 30 subjects, 5 central airway biopsies and 5 transbronchial biopsies (in total 124 300 biopsies) were collected during a study period from November 2005 to June 2010 at the 125 Department of Respiratory Medicine, Lund University Hospital (for methodological details, 126 see ref 27 and online supplement). All subjects gave their written informed consent to 127 participate in the study, which was approved by the ethics committee in Lund (LU412-03). 128
129
Lungs from patients with advanced stages of non-atopic patients with chronic obstructive 130 pulmonary disease (COPD) and cystic fibrosis were included to study the FcεRI expression 131 on alveolar mast cells in lungs subjected to a non-allergic inflammation. The clinical 132 characterization of these patients and their matching controls, are presented in the online 133 supplement and Table E2 . 134 subjects in all cohorts (controls, asthma, AR, COPD and CF) and was used to screen for 138 sensitization for 10 aeroallergens (birch, timothy, mugwort, cat, dog, horse, D. pteronyssinus, 139 D. farinae, Aspergillus fumigatus and Cladosporium herbarum). Atopy was defined as a 140 positive SPT (weal reaction larger or equal to histamine positive control) to one or more 141 allergens. Patients with positive SPT to pollen without any other sensitivity were classified as 142 seasonal, whereas patients with multiple sensitivities (pollen, animal, mould and/or mite) 143
were classified as perennial. For all subjects with positive SPT to seasonal pollen, 144 bronchoscopy procedures were performed outside pollen season. 145
146
Tissue Processing 147
Bronchial and Transbronchial biopsies 148
All biopsies from uncontrolled asthmatics and 4 out of 5 bronchial and 4 out of 5 149 transbronchial biopsies from the healthy controls were immediately placed in 4% buffered 150 formaldehyde, dehydrated, embedded in paraffin. Serial sections from all paraffin blocks were 151 stained with Mayer's haematoxylin and these were used to select 2 bronchial and 2 152 transbronchial biopsies from each patient that had a well-preserved morphology and were 153 without any crush, or mechanically-induced stretch artifacts. The selected biopsies were used 154 for quantification of mast cell-related parameters. 155
156
The remaining biopsies from the control patients and biopsies the rhinitis cohort were 157 immersed in periodate-lysine containing 1% paraformaldehyde (1% PLP) for 4 h at 4°C. 158
Specimens were embedded in OCT (Tissue-Tek, Miles Laboratories, IN), and frozen. Serial 159 cryo sections from all biopsies were generated and stored until histological assessments (see After triple immunofluorescence staining, the filter setting was adjusted to reveal the tryptase- 
Clinical Characteristics 211
An overview of the patient characteristics is presented in Table 1 . 212
Uncontrolled asthma: The 14 asthma patients included in the study had symptomatic 213 uncontrolled asthma (ACT score ranging from 11 to 21). All were atopic (i.e. positive SPT), 214 and all but one had rhinitis. All asthma patients were treated with inhaled glucocorticosteroids 215 (Budesonid) and inhaled bronchodilators (Table 1) . Two patients were treated with 216 leukotriene-receptor antagonists and 3 had nasal corticosteroids and anti-histamines p.r.n. In 
Controls 234
Densities of MC T and MC TC Populations 235
In central airways, the total tissue density of mast cells did not differ between patients with 236 uncontrolled asthma and healthy control subjects (Table 2 ). In contrast, the alveolar 237 parenchyma displayed increased numbers of mast cells in patients with uncontrolled asthma 238 compared to healthy controls ( Table 2 ). The unaltered total mast cell numbers in central 239 airways in uncontrolled asthma was a result of a decrease in MC T numbers combined with an 240 increase in MC TC numbers compared to healthy controls (Table 2 and Figure 1 ). The 241 significant increase in total alveolar mast cell numbers in uncontrolled asthmatics was due to 242 an increase in both MC T cells and MC TC numbers compared to healthy controls (Table 2 and 243
Figure 1). 244 245
Microlocalization of Mast Cell Subtypes in Central Airways 246
The highest density of mast cells was found in the lamina propria for both control subjects 247 and asthmatics. No difference in the distribution of mast cells was found for the MC T subclass 248 in asthmatics compared to controls (Table E3) (Table E3) . 251
252
Expression of FcεRIα and IgE on Bronchial and Alveolar Mast Cells 253
Both FcεRIα and IgE immunoreactivity displayed a characteristic membrane staining in 254 triple-stained immunofluorescence sections. As previously shown 12, 19, 38 , the proportion of 255 mast cell expressing FcεRIα was high in central airways in healthy subjects, and no 256 significant difference in expression to uncontrolled asthmatics was observed ( Figure 2A and Table 2 ). The mast cell expression of FcεRIα did not differ between controls and asthmatics, 258 neither for MC T (p = 0.4) nor for the MC TC subtype (p = 0.5). In contrast, in the alveolar 259 parenchyma, the mast cell expression of FcεRIα was low in healthy controls and significantly 260 higher in uncontrolled asthma ( Figure 2B , C-D and Table 2 ). The increased FcεRIα 261 expression in uncontrolled asthma was further confirmed using a computerized image 262 analysis approach was used to calculate the area of FcεRIα immunoreactivity on individual 263 mast cells (see online supplement). 264
265
In central airways, the proportion of IgE + mast cells was low in healthy controls and 266 significantly increased in uncontrolled asthmatics ( Figure 2E and Table 2 ). Also in the 267 alveolar parenchyma, the proportion of IgE + mast cells was low in controls and significantly 268 increased in the alveolar parenchyma ( Figure 2F , G-H and Table 2 ). As for the expression of 269 In AR, no significant change in total mast cell numbers or the density of MC T and MC TC was 283 found in central airways or in alveolar parenchyma compared to healthy controls (Table 2) . 284
No increase in the proportion of mast cells expressing the FcεRIα could be found in central 285 airways or in the alveolar parenchyma in patients with AR compared to controls (Table 2) (Table 2) . been demonstrated that measurements of thoracic gas volume and total lung capacity better 364 represents peripheral inflammation, and that these parameters correlate to e.g. distal 365
eosinophilic inflammation in patients with nocturnal asthma 37 . 366
367
In support of a beneficial effect of the ongoing treatment with ICS, the MC T population 368 decreased in central airways of asthmatics, while the MC TC numbers increased. As steroids 369 have previously been showed to reduce mast cell numbers in central airways and to mainly 370 affect the MC T population 57 , this observation implies an effect of ICS on mast cells in thebronchi. In contrast, both MC T and MC TC subpopulations increased significantly in the less 372 steroid-exposed alveolar parenchyma, which indicates that alveolar mast cell populations are 373 not well targeted by conventional ICS therapy. 374
375
Our data support the notion that patients who do not respond to conventional ICS therapy may 376 have a peripheral airway inflammation and should thus benefit from treatment strategies with 377 improved targeting of the distal lung 11, 58 . ICS, which are the foundation treatment of choice 378 for asthma patients 6, 59, 60 , were originally developed to primarily treat the central airways. 
